Article Details
Retrieved on: 2024-05-14 14:55:07
Tags for this article:
Click the tags to see associated articles and topics
Summary
Fennec Pharmaceuticals Inc. reported Q1 2024 financials, showing significant revenue growth from PEDMARK sales and a licensing deal with Norgine. The enhanced J-code for PEDMARK boosts its market positioning against ototoxicity from cisplatin, leveraging strategic assets and financial strength.
Article found on: investingnews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here